Kid’s long-term safety follow-up for OLZ and SAM treatment
Part of Mental health clinical trials.
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier related pediatric study recently (or stopped early due to a specific weight-gain rule)
- Your clinician believes you may benefit from continuing OLZ/SAM treatment
- You can take part as an outpatient (not staying in the hospital for study visits)
- There must be family support at home, and you must not be a safety risk to yourself or others
- A parent or legal guardian must reliably help with treatment, visit attendance, and study rules
- You must follow the study’s pregnancy prevention (contraception) requirements during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
This study tests the long-term safety of an investigational medication for schizophrenia over one year. It may be an option if you are currently stable on your antipsychotic medication.
This trial tests a new combination tablet (olanzapine-samidorphan) for adults with schizophrenia. It aims to see if it helps control symptoms while potentially reducing weight gain, which can be a side effect of some schizophrenia medicines.
This is an observational (non-intervention) study that follows adults with schizophrenia who are taking specific “atypical” antipsychotic medicines long-term. Researchers want to learn about patients’ experiences and outcomes while on these treatments.
This study is looking at the long-term safety of azetukalner for people with bipolar I or II depression who have already completed a previous trial of this drug. It is an open-label study, meaning everyone will receive the active medication.
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
Hear when a new Bipolar I Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.